{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:54:42Z","timestamp":1793055282495,"version":"4.5.0"},"reference-count":304,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"\n Introduction<\/jats:title>\n The clinical management of gynecologic malignancies endometrial (EC), ovarian (OC), and cervical (CC) carcinomas has been historically guided by histomorphology and staging. This paradigm fails to capture profound molecular heterogeneity, resulting in suboptimal outcomes. Precision oncology, through molecular taxonomy and biomarker-guided therapy, aims to address this gap.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This review synthesizes the current landscape of precision oncology in gynecologic cancers by analyzing established molecular classifications, the evidence for biomarker-guided therapies, mechanisms of therapeutic resistance, and emerging diagnostic and trial paradigms. The analysis is based on a critical evaluation of key literature and clinical trial data.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Molecular reclassification, exemplified by The Cancer Genome Atlas (TCGA) for EC and OC, has identified prognostically and therapeutically relevant subtypes. This has enabled successful clinical translation of targeted agents: PARP inhibitors for homologous recombination deficient (HRD) ovarian cancer, immune checkpoint inhibitors for mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) endometrial and cervical cancers, and antibody-drug conjugates (ADCs) like mirvetuximab soravtansine and tisotumab vedotin. However, acquired resistance to these therapies, driven by tumor evolution and heterogeneity, remains a pivotal barrier.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n The convergence of deep molecular phenotyping with targeted therapy is a cornerstone of modern care. Future directions require overcoming resistance through novel diagnostics like liquid biopsy, next-generation therapeutics, and innovative adaptive clinical trials. Equitable access to these advances is imperative to prevent widening health disparities. The field is evolving towards a model of continuous molecular monitoring and adaptive therapy to improve outcomes.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fonc.2026.1785469","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:32:06Z","timestamp":1775539926000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Precision oncology in gynecologic cancers: molecular taxonomy, biomarker-guided therapeutics, and the challenge of therapeutic resistance"],"prefix":"10.3389","volume":"16","author":[{"given":"Shanza","family":"Waseem","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Tianfu Jincheng Laboratory","place":["Chengdu, China"]},{"name":"Laboratory of Stem Cell and Embryo Development, West China Second Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Tianfu Jincheng Laboratory","place":["Chengdu, China"]},{"name":"Laboratory of Stem Cell and Embryo Development, West China Second Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Tianfu Jincheng Laboratory","place":["Chengdu, China"]},{"name":"Laboratory of Stem Cell and Embryo Development, West China Second Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Forensic Genetics, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.14.04155","article-title":"Global burden of gynaecological cancers in 2022 and projections to 2050","volume":"14","author":"Zhu","year":"2024","journal-title":"J Glob Health"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1002\/ijc.30901","article-title":"Cervical cancer in Africa, Latin America and the Caribbean and Asia: Regional inequalities and changing trends","volume":"141","author":"Vaccarella","year":"2017","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.04.024","article-title":"Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors","volume":"49","author":"Vaccarella","year":"2013","journal-title":"Eur J Cancer"},{"key":"B4","volume-title":"WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions. 1, Introduction","year":"2019"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(22)00501-0","article-title":"Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative","volume":"11","author":"Singh","year":"2023","journal-title":"Lancet Glob Health"},{"key":"B6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global cancer incidence and mortality rates and trends--an update","volume":"25","author":"Torre","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31795-0","article-title":"Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries","volume":"389","author":"Denny","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S1470-2045(18)30836-2","article-title":"Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study","volume":"20","author":"Simms","year":"2019","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35369","article-title":"Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: The urgent need to address inequalities in cervical cancer","volume":"157","author":"Li","year":"2025","journal-title":"Int J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.10.075","article-title":"Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends","volume":"163","author":"He","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2174\/138920371604150429151457","article-title":"Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance","volume":"16","author":"Wang","year":"2015","journal-title":"Curr Protein Pept Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1071383","article-title":"Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: a case report","volume":"12","author":"Bian","year":"2022","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-2025-641","article-title":"A real-world retrospective cohort study: the clinical outcomes and characteristics of platinum-resistant recurrent ovarian cancer","volume":"14","author":"Wang","year":"2025","journal-title":"Transl Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34757","article-title":"Targeted therapy for lung cancer: Beyond EGFR and ALK","volume":"129","author":"Herrera-Ju\u00e1rez","year":"2023","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv098","article-title":"A decision support framework for genomically informed investigational cancer therapy","volume":"107","author":"Meric-Bernstam","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"B16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.clcc.2019.02.008","article-title":"A genomic analysis workflow for colorectal cancer precision oncology","volume":"18","author":"Corti","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/5113990","article-title":"Machine learning-based integrated analysis of PANoptosis patterns in acute myeloid leukemia reveals a signature predicting survival and immunotherapy","volume":"2024","author":"Tang","year":"2024","journal-title":"Int J Clin Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.5483\/bmbrep.2016.49.11.145","article-title":"Exploring cancer genomic data from the cancer genome atlas project","volume":"49","author":"Lee","year":"2016","journal-title":"BMB Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.cell.2018.03.033","article-title":"Perspective on oncogenic processes at the end of the beginning of cancer genomics","volume":"173","author":"Ding","year":"2018","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1146499","article-title":"Integrated clinicopathologic and molecular analysis of endometrial carcinoma: Prognostic impact of the new ESGO-ESTRO-ESP endometrial cancer risk classification and proposal of histopathologic algorithm for its implementation in clinical practice","volume":"10","author":"de Biase","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13050723","article-title":"Prognostic impact of pathologic features in molecular subgroups of endometrial carcinoma","volume":"13","author":"Ruscelli","year":"2023","journal-title":"J Pers Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.311","article-title":"PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: current practice and future directions","volume":"115","author":"Konecny","year":"2016","journal-title":"Br J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e3283564230","article-title":"Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer","volume":"24","author":"Ratner","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s12032-025-02817-y","article-title":"Precision oncology: transforming cancer care through personalized medicine","volume":"42","author":"Rituraj","year":"2025","journal-title":"Med Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-018-0127-4","article-title":"Data-driven methods for advancing precision oncology","volume":"4","author":"Nedungadi","year":"2018","journal-title":"Curr Pharmacol Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.09.029","article-title":"Clinical assays for assessment of homologous recombination DNA repair deficiency","volume":"159","author":"Stover","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.11.014","article-title":"A standardized measurement and valuation scale of genomic utility for policy decisions: the GUV scale","volume":"28","author":"Goranitis","year":"2025","journal-title":"Value Health"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/path.5034","article-title":"The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses","volume":"244","author":"McAlpine","year":"2018","journal-title":"J Pathol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.05.059","article-title":"Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma","volume":"174","author":"Rios-Doria","year":"2023","journal-title":"Gynecol Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11912-021-01073-3","article-title":"Impact of molecular classification on treatment paradigms in uterine cancers","volume":"23","author":"Cosgrove","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12885-023-10706-8","article-title":"Clinical characteristics and prognostic characterization of endometrial carcinoma: a comparative analysis of molecular typing protocols","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000000898","article-title":"Targeted molecular testing in endometrial carcinoma: validation of a clinically driven selective ProMisE testing protocol","volume":"42","author":"Talhouk","year":"2023","journal-title":"Int J Gynecol Pathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35596","article-title":"Challenges in implementation of molecular classification in early stage endometrial cancer-an NRG Oncology cooperative group mixed-methods study","volume":"131","author":"Wilson","year":"2025","journal-title":"Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3109\/09513590.2011.649595","article-title":"New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications","volume":"28","author":"Gadducci","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am J Pathol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s12885-022-09602-4","article-title":"Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer","volume":"22","author":"Wen","year":"2022","journal-title":"BMC Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41523-023-00561-y","article-title":"Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1\/2mut carriers in the ABRAZO study","volume":"9","author":"Turner","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118434","article-title":"Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy","volume":"261","author":"Gou","year":"2020","journal-title":"Life Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.04.586","article-title":"Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors","volume":"197","author":"Evans","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235525","article-title":"Concordance between three homologous recombination deficiency (HRD) assays in patients with high-grade epithelial ovarian cancer","volume":"15","author":"Fountzilas","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ygyno.2024.01.016","article-title":"Concordance between an FDA-approved companion diagnostic and an alternative assay kit for assessing homologous recombination deficiency in ovarian cancer","volume":"184","author":"Wehn","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13551","article-title":"FDA approval summary: Olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer","volume":"26","author":"Arora","year":"2021","journal-title":"Oncologist"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.32074\/1591-951X-791","article-title":"In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay","volume":"114","author":"Fumagalli","year":"2022","journal-title":"Pathologica"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2022.09.004","article-title":"Homologous recombination deficiency as an ovarian cancer biomarker in a real-world cohort: validation of decentralized genomic profiling","volume":"24","author":"Denkert","year":"2022","journal-title":"J Mol Diagn"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35523","article-title":"Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer","volume":"131","author":"Sullivan","year":"2025","journal-title":"Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17199","article-title":"Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences","volume":"8","author":"Cho","year":"2017","journal-title":"Oncotarget"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2024.34139","article-title":"Implementing MyChoice\u00ae CDx HRD testing for the Nordics: lessons from 2021 to 2023","volume":"63","author":"Korsholm","year":"2024","journal-title":"Acta Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13213293","article-title":"A benchmark of in-house homologous recombination repair deficiency testing solutions for high-grade serous ovarian cancer diagnosis","volume":"13","author":"Guarischi-Sousa","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/jcp-2023-208852","article-title":"In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study","volume":"77","author":"Pepe","year":"2024","journal-title":"J Clin Pathol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-024-01603-4","article-title":"Neoadjuvant talazoparib in patients with germline BRCA1\/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status","volume":"31","author":"Telli","year":"2024","journal-title":"Breast Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47080638","article-title":"Homologous recombination deficiency in ovarian and breast cancers: Biomarkers, diagnosis, and treatment","volume":"47","author":"Shah","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114127","article-title":"Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A\/MaNGO-OV2 trial","volume":"206","author":"Roma","year":"2024","journal-title":"Eur J Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.04.020","article-title":"PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1\/ENGOT-ov25 trial","volume":"188","author":"Loverix","year":"2023","journal-title":"Eur J Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030818","article-title":"Implementing HRD testing in routine clinical practice on patients with primary high-grade advanced ovarian cancer","volume":"15","author":"Heitz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100445","article-title":"Systematic analysis of homologous recombination deficiency testing in ovarian cancer-development of recommendations for optimal assay performance","volume":"37","author":"Romey","year":"2024","journal-title":"Mod Pathol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14041098","article-title":"Toward more comprehensive homologous recombination deficiency assays in ovarian cancer part 2: Medical perspectives","volume":"14","author":"Quesada","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010043","article-title":"Locally performed HRD testing for ovarian cancer? Yes, we can","volume":"15","author":"Magliacane","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.01.003","article-title":"Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer","volume":"35","author":"Harvey-Jones","year":"2024","journal-title":"Ann Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/978-3-031-30065-3_4","article-title":"Development of homologous recombination functional assays for targeting the DDR","volume":"186","author":"Oswald","year":"2023","journal-title":"Cancer Treat Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13073-024-01413-5","article-title":"Patterns of genomic instability in\u2009>\u20092000 patients with ovarian cancer across six clinical trials evaluating olaparib","volume":"16","author":"Barnicle","year":"2024","journal-title":"Genome Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100585","article-title":"Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A\/MaNGO-OV2 trial","volume":"7","author":"Capoluongo","year":"2022","journal-title":"ESMO Open"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.01.026","article-title":"A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer","volume":"171","author":"Blanc-Durand","year":"2023","journal-title":"Gynecol Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3156","article-title":"Functional homologous recombination assay on FFPE specimens of advanced high-grade serous ovarian cancer predicts clinical outcomes","volume":"29","author":"Pikkusaari","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.08.035","article-title":"Homologous recombination deficiency real-time clinical assays, ready or not","volume":"159","author":"Fuh","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04831-x","article-title":"Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine","volume":"149","author":"Cai","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/genes12071103","article-title":"Classification of high-grade serous ovarian carcinoma by epithelial-to-mesenchymal transition signature and homologous recombination repair genes","volume":"12","author":"Sohn","year":"2021","journal-title":"Genes (Basel)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.13553","article-title":"Multi-omics-based analysis of high grade serous ovarian cancer subtypes reveals distinct molecular processes linked to patient prognosis","volume":"13","author":"Wang","year":"2023","journal-title":"FEBS Open Bio"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.2147\/PGPM.S24943","article-title":"Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer","volume":"6","author":"Leamon","year":"2013","journal-title":"Pharmgenomics Pers Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_438582","article-title":"Updates in the use of targeted therapies for gynecologic cancers","volume":"44","author":"Cantillo","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.05.015","article-title":"Endometrial cancer: Molecular markers and management of advanced stage disease","volume":"150","author":"Arend","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1061761","article-title":"Evaluation of immunotherapy efficacy in gynecologic cancer","volume":"14","author":"Jiang","year":"2023","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ygyno.2016.01.003","article-title":"Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know","volume":"141","author":"Liu","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0310736","article-title":"Mirvetuximab soravtansine in solid tumors: A systematic review and meta-analysis","volume":"19","author":"Rehim","year":"2024","journal-title":"PloS One"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12081903","article-title":"Comprehensive approach to genomic and immune profiling: Insights of a real-world experience in gynecological tumors","volume":"12","author":"Prieto-Potin","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00406","article-title":"Vulvar squamous cell carcinoma: Comprehensive genomic profiling of HPV+ versus HPV- forms reveals distinct sets of potentially actionable molecular targets","volume":"4","author":"Williams","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","year":"2017","journal-title":"Nature"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.07.006","article-title":"Treatment of metastatic cervical cancer: future directions involving targeted agents","volume":"85","author":"Diaz-Padilla","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10238-025-01965-9","article-title":"AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions","volume":"26","author":"Hsu","year":"2025","journal-title":"Clin Exp Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.03.006","article-title":"Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives","volume":"36","author":"Marra","year":"2025","journal-title":"Ann Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.0c04850","article-title":"Multiomic big data analysis challenges: Increasing confidence in the interpretation of artificial intelligence assessments","volume":"93","author":"Odenkirk","year":"2021","journal-title":"Anal Chem"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004580","article-title":"New windows of surgical opportunity for gynecological cancers in the era of targeted therapies","volume":"34","author":"Peters","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.3701","article-title":"Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges","volume":"27","author":"Mandrekar","year":"2009","journal-title":"J Clin Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2304-3865.2014.05.03","article-title":"Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine","volume":"3","author":"Mandrekar","year":"2014","journal-title":"Chin Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00416","article-title":"Phase III precision medicine clinical trial designs that integrate treatment and biomarker evaluation","volume":"3","author":"Polley","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1335196","article-title":"How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer: a review of literature","volume":"14","author":"Arcieri","year":"2024","journal-title":"Front Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1558185","article-title":"PARP inhibitors for recurrent ovarian carcinoma: current treatment options and future perspectives","volume":"76","author":"Sehouli","year":"2016","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-018-0572-7","article-title":"Using PARP inhibitors in the treatment of patients with ovarian cancer","volume":"19","author":"Kurnit","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ygyno.2017.10.003","article-title":"PARP inhibitors: Clinical utility and possibilities of overcoming resistance","volume":"147","author":"Bitler","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02589","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update","volume":"43","author":"Gaillard","year":"2025","journal-title":"J Clin Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.08.024","article-title":"Combination ATR and PARP inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer","volume":"163","author":"Shah","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","first-page":"22659","DOI":"10.1038\/s41598-023-50151-y","article-title":"Targeted inhibition of the ATR\/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells","volume":"13","author":"Biega\u0142a","year":"2023","journal-title":"Sci Rep"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167574","article-title":"Molecular mechanisms restoring olaparib efficacy through ATR\/CHK1 pathway inhibition in olaparib-resistant BRCA1\/2MUT ovarian cancer models","volume":"1871","author":"Biega\u0142a","year":"2025","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.05.002","article-title":"A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib","volume":"187","author":"Liu","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000320","article-title":"DNA damage response as a therapeutic target in gynecological cancers","volume":"28","author":"Leary","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.754524","article-title":"Perspectives on PARP inhibitor combinations for ovarian cancer","volume":"11","author":"Bonadio","year":"2021","journal-title":"Front Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2021.1933585","article-title":"High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer","volume":"60","author":"M\u00f6ller","year":"2021","journal-title":"Acta Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2213","article-title":"Biomarkers of pathologic complete response to neoadjuvant immunotherapy in mismatch repair-deficient colorectal cancer","volume":"30","author":"Li","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.12.020","article-title":"Pembrolizumab in microsatellite instability-high\/mismatch repair deficient (MSI-H\/dMMR) and non-MSI-H\/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results","volume":"193","author":"O'Malley","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3915","article-title":"Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: Interim results of the phase I GARNET study","volume":"29","author":"Oaknin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"B104","volume-title":"National institute for health and care excellence: technology appraisals, no. TA939","year":"2023"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104084","article-title":"Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: A systematic review and meta-analysis","volume":"189","author":"Fu","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1158\/2159-8290.CD-NB2018-086","article-title":"Pembrolizumab OK'd for cervical cancer","volume":"8","year":"2018","journal-title":"Cancer Discov"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5410","article-title":"Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses from the KEYNOTE-826 randomized clinical trial","volume":"10","author":"Tewari","year":"2024","journal-title":"JAMA Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14148","article-title":"Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial","volume":"110","author":"Tamura","year":"2019","journal-title":"Cancer Sci"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: Results from the phase I\/II CheckMate 358 trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J Clin Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102431","article-title":"Concordance, correlation, and clinical impact of standardized PD-L1 and TIL scoring in SCCHN","volume":"14","author":"De Keukeleire","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B113","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ijc.30770","article-title":"The PD-1\/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)","volume":"141","author":"Balermpas","year":"2017","journal-title":"Int J Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0221","article-title":"FDA approval summary: Pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1","volume":"24","author":"Fashoyin-Aje","year":"2019","journal-title":"Oncologist"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0498","article-title":"FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1","volume":"21","author":"Sul","year":"2016","journal-title":"Oncologist"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000002058","article-title":"Interobserver agreement on the interpretation of programmed death-ligand 1 (PD-L1) combined positive score (CPS) among gynecologic pathologists","volume":"47","author":"Mills","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001633","article-title":"PD-L1 expression in endocervical adenocarcinoma: Correlation with patterns of tumor invasion, CD8+ tumor-infiltrating lymphocytes, and clinical outcomes","volume":"45","author":"Rivera-Colon","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920963001","article-title":"PD-L1 protein expression and copy number gains in HIV-positive locally advanced cervical cancer","volume":"12","author":"Loharamtaweethong","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"12974","DOI":"10.1038\/s41598-024-63595-7","article-title":"PD-L1 expression in squamous cervical carcinomas of Mozambican women living with or without HIV","volume":"14","author":"Lovane","year":"2024","journal-title":"Sci Rep"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2019.07.003","article-title":"The role of biomarkers for the prediction of response to checkpoint immunotherapy and the rationale for the use of checkpoint immunotherapy in cervical cancer","volume":"31","author":"Otter","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2019.303644","article-title":"Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients","volume":"65","author":"Duffy","year":"2019","journal-title":"Clin Chem"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1078","article-title":"Assessing the genomic landscape of cervical cancers: Clinical opportunities and therapeutic targets","volume":"29","author":"Friedman","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","first-page":"20495","DOI":"10.1038\/s41598-022-23319-1","article-title":"A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours","volume":"12","author":"Kang","year":"2022","journal-title":"Sci Rep"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010136","article-title":"Genomic landscape of endometrial, ovarian, and cervical cancers in Japan from the database in the Center for Cancer Genomics and Advanced Therapeutics","volume":"16","author":"Xi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02767","article-title":"Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion","volume":"40","author":"Chakravarty","year":"2022","journal-title":"J Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003091","article-title":"Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: A pan-tumor retrospective analysis of participants with advanced solid tumors","volume":"10","author":"Cristescu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"B128","article-title":"De l'utilit\u00e9 d'une consultation conjointe de gyn\u00e9cologie- endocrinologie p\u00e9diatrique: etude r\u00e9trospective des motifs de consultation et approche pratique [The usefulness of combined gynecologic and endocrinologic consultation in pediatrics: a retrospective study of the reasons for consultation and the practical approach","volume":"66","author":"Harvengt","year":"2011","journal-title":"Rev Med Liege"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: Is more always better","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2024.48.90.42773","article-title":"The interplay between programmed death ligand 1 (PD-L1) expression and human papillomavirus (HPV) genotypes in cervical carcinomas: Findings of a Nigerian tertiary hospital","volume":"48","author":"Omenai","year":"2024","journal-title":"Pan Afr Med J"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001800","article-title":"The prognostic values of HPV genotypes and tumor PD-L1 expression in patients with HPV-associated endocervical adenocarcinoma","volume":"46","author":"Zhou","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00914","article-title":"High-risk HPV oncoproteins and PD-1\/PD-L1 interplay in human cervical cancer: Recent evidence and future directions","volume":"10","author":"Allouch","year":"2020","journal-title":"Front Oncol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"14064","DOI":"10.1038\/s41598-021-93485-1","article-title":"Mixed and nonvaccine high risk HPV types are associated with higher mortality in Black women with cervical cancer","volume":"11","author":"Mendoza","year":"2021","journal-title":"Sci Rep"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-021-01308-6","article-title":"Comparing outcomes for patients with human papillomavirus (HPV) type 16 versus other high-risk HPV types in oropharyngeal squamous cell carcinoma","volume":"15","author":"Shenker","year":"2021","journal-title":"Head Neck Pathol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3329","article-title":"Transcriptomic determinants of response to pembrolizumab monotherapy across solid tumor types","volume":"28","author":"Cristescu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B137","article-title":"StatPearls [Internet]","author":"Menon","year":"2024"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00780-3","article-title":"Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma","volume":"34","author":"Huang","year":"2021","journal-title":"Mod Pathol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2014.05.012","article-title":"APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development","volume":"7","author":"Henderson","year":"2014","journal-title":"Cell Rep"},{"key":"B141","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12920-019-0579-3","article-title":"Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types","volume":"12","author":"Chen","year":"2019","journal-title":"BMC Med Genomics"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14113","article-title":"The immune response-related mutational signatures and driver genes in non-small-cell lung cancer","volume":"110","author":"Chen","year":"2019","journal-title":"Cancer Sci"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2017.01103","article-title":"APOBEC-mediated genomic alterations link immunity and viral infection during human papillomavirus-driven cervical carcinogenesis","volume":"11","author":"Chen","year":"2017","journal-title":"Biosci Trends"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.683419","article-title":"FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6743126","article-title":"Prognostic nutritional index predicts outcome of PD-L1 negative and MSS advanced cancer treated with PD-1 inhibitors","volume":"2022","author":"Zhang","year":"2022","journal-title":"BioMed Res Int"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.08.017","article-title":"Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer","volume":"77","author":"Le Saux","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11912-018-0740-8","article-title":"Combination immune checkpoint blockade strategies to maximize immune response in gynecological cancers","volume":"20","author":"Liu","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173867","article-title":"The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy","volume":"895","author":"Setordzi","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B149","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s12957-023-03212-5","article-title":"Neoadjuvant PD-1\/PD-L1 combined with CTLA-4 inhibitors for solid Malignancies: A systematic review and meta-analysis","volume":"21","author":"Huang","year":"2023","journal-title":"World J Surg Oncol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1208\/s12248-020-00514-4","article-title":"Identification and utilization of biomarkers to predict response to immune checkpoint inhibitors","volume":"22","author":"Gjoerup","year":"2020","journal-title":"AAPS J"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: State of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101086","article-title":"Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement","volume":"75","author":"Jiang","year":"2024","journal-title":"Drug Resist Update"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101978","article-title":"Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets","volume":"35","author":"He","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2023.100952","article-title":"Tisotumab vedotin in recurrent or metastatic cervical cancer","volume":"47","author":"Bogani","year":"2023","journal-title":"Curr Probl Cancer"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.02.010","article-title":"Mitigation and management strategies for ocular events associated with tisotumab vedotin","volume":"165","author":"Kim","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00021-X","article-title":"Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor \u03b1-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial","volume":"26","author":"Van Gorp","year":"2025","journal-title":"Lancet Oncol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1186\/s12885-024-13226-1","article-title":"Real-world evidence of trastuzumab deruxtecan (T-DXd) efficacy in HER2-expressing gynecological Malignancies","volume":"24","author":"Andrikopoulou","year":"2024","journal-title":"BMC Cancer"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2025.07.024","article-title":"HER2 expression in an endometrial cancer cohort","volume":"201","author":"Hacker","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy023","article-title":"Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study","volume":"29","author":"Banerjee","year":"2018","journal-title":"Ann Oncol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.04.023","article-title":"SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2\/Neu expression","volume":"146","author":"Menderes","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ygyno.2025.06.016","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer","volume":"200","author":"Matulonis","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102546","article-title":"The evolving landscape of antibody-drug conjugates in gynecologic cancers","volume":"116","author":"Tolcher","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0662","article-title":"The PI3K\/AKT\/mTOR pathway as a therapeutic target in endometrial cancer","volume":"18","author":"Slomovitz","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4809751","article-title":"A review of mTOR pathway inhibitors in gynecologic cancer","volume":"2017","author":"de Melo","year":"2017","journal-title":"Oxid Med Cell Longev"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1547083","article-title":"AKT inhibitors in gynecologic oncology: past, present and future","volume":"15","author":"Chen","year":"2025","journal-title":"Front Oncol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27770","article-title":"A systematic review and meta-analysis of selected toxicity endpoints of alpelisib","volume":"11","author":"Shields","year":"2020","journal-title":"Oncotarget"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.04.005","article-title":"Metabolic complications with the use of mTOR inhibitors for cancer therapy","volume":"40","author":"Sivendran","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0704","article-title":"Allosteric PI3K\u03b1 inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations","volume":"14","author":"Varkaris","year":"2024","journal-title":"Cancer Discov"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241241531","article-title":"Capivasertib: A novel AKT inhibitor approved for hormone-receptor-positive, HER-2-negative metastatic breast cancer","volume":"58","author":"Luboff","year":"2024","journal-title":"Ann Pharmacother"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103997","article-title":"Practical treatment strategies and novel therapies in the phosphoinositide 3-kinase (PI3K)\/protein kinase B (AKT)\/mammalian target of rapamycin (mTOR) pathway in hormone receptor-positive\/human epidermal growth factor receptor 2 (HER2)-negative (HR+\/HER2-) advanced breast cancer","volume":"9","author":"Fanucci","year":"2024","journal-title":"ESMO Open"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aao3810","article-title":"Skp2-dependent reactivation of AKT drives resistance to PI3K inhibitors","volume":"11","author":"Clement","year":"2018","journal-title":"Sci Signal"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.12703\/P7-13","article-title":"The phosphoinositide 3-kinase pathway and therapy resistance in cancer","volume":"7","author":"Brown","year":"2015","journal-title":"F1000Prime Rep"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103334","article-title":"PI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance","volume":"162","author":"Vitale","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16122259","article-title":"Resistance to targeted inhibitors of the PI3K\/AKT\/mTOR pathway in advanced oestrogen-receptor-positive breast cancer","volume":"16","author":"Browne","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05618-1","article-title":"Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer","volume":"181","author":"Drullinsky","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B178","doi-asserted-by":"publisher","first-page":"27","DOI":"10.20517\/cdr.2024.189","article-title":"Acquired resistance to molecularly targeted therapies for cancer","volume":"8","author":"Stubbs","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: learning from lung cancer","volume":"11","author":"Camidge","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3715","article-title":"Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B182","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/GCO.0000000000000600","article-title":"Mechanisms of PARP inhibitor resistance in ovarian cancer","volume":"32","author":"Kubalanza","year":"2020","journal-title":"Curr Opin Obstet Gynecol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1484802","article-title":"Negative response to immunotherapy in dMMR or MSI-H gastric cancer with APC and PTEN mutations: a case report","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004749","article-title":"Resistance to systemic immune checkpoint inhibition in the peritoneal niche","volume":"10","author":"Chia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17060958","article-title":"Opportunities and challenges in antibody-drug conjugates for cancer therapy: A new era for cancer treatment","volume":"17","author":"Buyukgolcigezli","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041278","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"15","author":"Abelman","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1300","article-title":"SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads","volume":"24","author":"Kinneer","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgac063","article-title":"SLC46A3 is a lysosomal proton-coupled steroid conjugate and bile acid transporter involved in transport of active catabolites of T-DM1","volume":"1","author":"Tomabechi","year":"2022","journal-title":"PNAS Nexus"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105012","article-title":"Epigenetic mechanisms of PARP inhibitor resistance in ovarian cancer: A systematic review with bioinformatic analysis of clinically actionable genes","volume":"217","author":"Habiburrahman","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"B190","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/s42003-024-06909-9","article-title":"The chromatin landscape of high-grade serous ovarian cancer metastasis identifies regulatory drivers in post-chemotherapy residual tumour cells","volume":"7","author":"Croft","year":"2024","journal-title":"Commun Biol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3971","article-title":"Inhibition of the MYC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant ovarian cancers","volume":"80","author":"Shen","year":"2020","journal-title":"Cancer Res"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911217","article-title":"Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors","volume":"12","author":"Lahiguera","year":"2020","journal-title":"EMBO Mol Med"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.adl6445","article-title":"Metabolically inducing defects in DNA repair sensitizes BRCA-wild-type cancer cells to replication stress","volume":"17","author":"Watanabe","year":"2024","journal-title":"Sci Signal"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112666","article-title":"Emerging insights into targeted therapy-tolerant persister cells in cancer","volume":"13","author":"Cabanos","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.03.026","article-title":"Mitochondrial fatty acid oxidation as the target for blocking therapy-resistance and inhibiting tumor recurrence: The proof-of-principle model demonstrated for ovarian cancer cells","volume":"79","author":"Lin","year":"2026","journal-title":"J Adv Res"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0881","article-title":"Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling","volume":"70","author":"Sullivan","year":"2010","journal-title":"Cancer Res"},{"key":"B197","doi-asserted-by":"publisher","first-page":"6072","DOI":"10.1038\/s41598-025-90963-8","article-title":"Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer","volume":"15","author":"Wu","year":"2025","journal-title":"Sci Rep"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-020-00578-6","article-title":"Clinical perspectives of BET inhibition in ovarian cancer","volume":"44","author":"Andrikopoulou","year":"2021","journal-title":"Cell Oncol (Dordr)"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.103986","article-title":"Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics","volume":"29","author":"Bao","year":"2024","journal-title":"Drug Discov Today"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1261\/rna.053108.115","article-title":"Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages","volume":"22","author":"Effenberger","year":"2016","journal-title":"RNA"},{"key":"B201","doi-asserted-by":"publisher","first-page":"176","DOI":"10.21037\/atm.2019.03.63","article-title":"SF3B1 mutation predicts unfavorable treatment-free survival in Chinese chronic lymphocytic leukemia patients","volume":"7","author":"Miao","year":"2019","journal-title":"Ann Transl Med"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202000642","article-title":"A comprehensive overview of structure-activity relationships of small-molecule splicing modulators targeting SF3B1 as anticancer agents","volume":"15","author":"Zhang","year":"2020","journal-title":"ChemMedChem"},{"key":"B203","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41392-023-01409-4","article-title":"Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases","volume":"8","author":"Song","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01328-9","article-title":"Phase I first-in-human dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms","volume":"35","author":"Steensma","year":"2021","journal-title":"Leukemia"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S220267","article-title":"Akt\/mTOR-mediated autophagy confers resistance to BET inhibitor JQ1 in ovarian cancer","volume":"12","author":"Luan","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3669-6","article-title":"Autophagy modulation: a prudent approach in cancer treatment","volume":"82","author":"Bishop","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.08.069","article-title":"Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease","volume":"47","author":"Hickson","year":"2019","journal-title":"EBioMedicine"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.04.045","article-title":"Preclinical antitumor efficacy of senescence-inducing chemotherapy combined with a nanosSenolytic","volume":"323","author":"Galiana","year":"2020","journal-title":"J Control Release"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac025","article-title":"Hypoxia-inducible factor 2 alpha (HIF2\u03b1) inhibitors: targeting genetically driven tumor hypoxia","volume":"44","author":"Toledo","year":"2023","journal-title":"Endocr Rev"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0758-4","article-title":"Paracrine and epigenetic control of CAF-induced metastasis: the role of HOTAIR stimulated by TGF-\u00df1 secretion","volume":"17","author":"Ren","year":"2018","journal-title":"Mol Cancer"},{"key":"B212","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cell.2018.01.009","article-title":"CD10+GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness","volume":"172","author":"Su","year":"2018","journal-title":"Cell"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.9564","article-title":"HALO 202: Randomized phase II study of PEGPH20 plus nab-paclitaxel\/gemcitabine versus nab-paclitaxel\/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma","volume":"36","author":"Hingorani","year":"2018","journal-title":"J Clin Oncol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01295","article-title":"Phase IB\/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313","volume":"37","author":"Ramanathan","year":"2019","journal-title":"J Clin Oncol"},{"key":"B215","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s40360-024-00828-5","article-title":"The efficacy and safety of belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis","volume":"25","author":"Song","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0949-5","article-title":"Mitochondrial fission causes cisplatin resistance under hypoxic conditions via ROS in ovarian cancer cells","volume":"38","author":"Han","year":"2019","journal-title":"Oncogene"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.12.127","article-title":"Inhibition of mitochondrial translation as a therapeutic strategy for human ovarian cancer to overcome chemoresistance","volume":"509","author":"Hu","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"B218","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1038\/s41467-020-15596-z","article-title":"Exploiting evolutionary steering to induce collateral drug sensitivity in cancer","volume":"11","author":"Acar","year":"2020","journal-title":"Nat Commun"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1038\/s41559-021-01428-w","article-title":"A theoretical analysis of tumour containment","volume":"5","author":"Viossat","year":"2021","journal-title":"Nat Ecol Evol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8020205","article-title":"An integrative systems biology and experimental approach identifies convergence of epithelial plasticity, metabolism, and autophagy to promote chemoresistance","volume":"8","author":"Xu","year":"2019","journal-title":"J Clin Med"},{"key":"B221","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-019-0818-2","article-title":"Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy","volume":"12","author":"Lim","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B222","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12935-025-03734-w","article-title":"Intratumoral heterogeneity and drug resistance in cancer","volume":"25","author":"Fu","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B223","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.1038\/s41467-022-33069-3","article-title":"Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones","volume":"13","author":"Marklund","year":"2022","journal-title":"Nat Commun"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-020-05853-1","article-title":"Chemotherapy resistance and stromal targets in breast cancer treatment: a review","volume":"47","author":"van der Spek","year":"2020","journal-title":"Mol Biol Rep"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1634413","article-title":"Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming","volume":"16","author":"Chen","year":"2025","journal-title":"Front Pharmacol"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.988956","article-title":"Overcoming the therapeutic resistance of hepatomas by targeting the tumor microenvironment","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172804","article-title":"Anti-EGFR therapy in metastatic colorectal cancer: identifying, tracking, and overcoming resistance","volume":"17","author":"Leite","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102519","article-title":"Clinical applications of cell-free DNA-based liquid biopsy analysis","volume":"61","author":"Yazaki","year":"2025","journal-title":"Transl Oncol"},{"key":"B229","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0393","article-title":"Early detection of ovarian cancer using cell-free DNA fragmentomes and protein biomarkers","volume":"15","author":"Medina","year":"2025","journal-title":"Cancer Discov"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401760","article-title":"Performance of liquid biopsy-based multi-omics biomarkers for early detection of gynecological Malignancies: a prospective study (PERCEIVE-I)","volume":"12","author":"Feng","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B232","doi-asserted-by":"publisher","first-page":"6042","DOI":"10.1038\/s41467-023-41774-w","article-title":"Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization","volume":"14","author":"Bie","year":"2023","journal-title":"Nat Commun"},{"key":"B233","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ygyno.2022.07.008","article-title":"Blood-based DNA methylation profiling for the detection of ovarian cancer","volume":"167","author":"Li","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.03.018","article-title":"Methylated DNA markers for plasma detection of ovarian cancer: discovery, validation, and clinical feasibility","volume":"165","author":"Marinelli","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13108","article-title":"BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer","volume":"15","author":"Elazezy","year":"2021","journal-title":"Mol Oncol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.70071","article-title":"The INSPECTOR study: enhanced feasibility for clinical translation of a multi-cancer early detection method based on enzyme-assisted high signal-to-noise ratio sequencing of methylated circulating tumor DNA","volume":"45","author":"Luo","year":"2025","journal-title":"Cancer Commun (Lond)"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2209852119","article-title":"Epigenetic analysis of cell-free DNA by fragmentomic profiling","volume":"119","author":"Zhou","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70361","article-title":"A multicenter cohort study on DNA methylation for endometrial cancer detection in cervical scrapings","volume":"13","author":"Ma","year":"2024","journal-title":"Cancer Med"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174343","article-title":"Endometrial cancer detection using a cervical DNA methylation assay (MPap) in women with abnormal uterine bleeding: a multicenter hospital-based validation study","volume":"14","author":"Wen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2023-0541","article-title":"Ultra-short cell-free DNA fragments enhance cancer early detection in a multi-analyte blood test combining mutation, protein and fragmentomics","volume":"62","author":"Wang","year":"2023","journal-title":"Clin Chem Lab Med"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34981","article-title":"Fragmentomics features of ovarian cancer","volume":"155","author":"Chao","year":"2024","journal-title":"Int J Cancer"},{"key":"B242","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41525-026-00553-4","article-title":"Semi-automated genomic newborn screening highlights complexities in reporting","volume":"11","author":"Chowdhury","year":"2026","journal-title":"NPJ Genom Med"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2012.640836","article-title":"Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials","volume":"47","author":"Shi","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2021.09.005","article-title":"Lightning does strike twice: leveraging phased variants to enhance minimal residual disease detection","volume":"2","author":"Cheng","year":"2021","journal-title":"Med"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e39148","article-title":"Advances and challenges in the use of liquid biopsy in gynaecological oncology","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02694-5","article-title":"Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies","volume":"30","author":"Imai","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2025.06.030","article-title":"Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation","volume":"70","author":"Xu","year":"2025","journal-title":"Sci Bull (Beijing)"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2022.154267","article-title":"The role of tumor-educated platelets in ovarian cancer: a comprehensive review and update","volume":"241","author":"Patel","year":"2023","journal-title":"Pathol Res Pract"},{"key":"B249","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12943-022-01588-8","article-title":"Potential clinical utility of liquid biopsies in ovarian cancer","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol Cancer"},{"key":"B250","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13048-021-00814-z","article-title":"Plasma-derived exosomal miR-4732-5p is a promising noninvasive diagnostic biomarker for epithelial ovarian cancer","volume":"14","author":"Liu","year":"2021","journal-title":"J Ovarian Res"},{"key":"B251","doi-asserted-by":"publisher","first-page":"4996","DOI":"10.1021\/jacs.9b13960","article-title":"Thermophoretic detection of exosomal microRNAs by nanoflares","volume":"142","author":"Zhao","year":"2020","journal-title":"J Am Chem Soc"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101433","article-title":"Circulating exosomal miRNAs as biomarkers in epithelial ovarian cancer","volume":"9","author":"Shiao","year":"2021","journal-title":"Biomedicines"},{"key":"B253","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3892\/ijmm.2024.5411","article-title":"Role of exosomal non-coding RNAs in ovarian cancer (review)","volume":"54","author":"Wang","year":"2024","journal-title":"Int J Mol Med"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2025.120771","article-title":"Exosomal microRNA biomarkers in ovarian cancer detection: systematic review and meta-analysis","volume":"584","author":"Huang","year":"2026","journal-title":"Clin Chim Acta"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107458","article-title":"Circulating tumor DNA as an early cancer detection tool","volume":"207","author":"Campos-Carrillo","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B256","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13148-023-01440-w","article-title":"Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review","volume":"15","author":"Terp","year":"2023","journal-title":"Clin Epigenet"},{"key":"B257","doi-asserted-by":"publisher","first-page":"17288","DOI":"10.1038\/s41598-024-68249-2","article-title":"Large-scale proteomics reveals precise biomarkers for detection of ovarian cancer in symptomatic women","volume":"14","author":"Ivansson","year":"2024","journal-title":"Sci Rep"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241233225","article-title":"Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4","volume":"16","author":"Ghose","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105770","article-title":"Early detection, clinicopathological subtyping, and prognosis prediction for endometrial cancer patients using fragmentomics liquid biopsy assay","volume":"10","author":"Rao","year":"2025","journal-title":"ESMO Open"},{"key":"B260","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s12032-023-02128-0","article-title":"Liquid biopsy in ovarian cancer: advantages and limitations for prognosis and diagnosis","volume":"40","author":"Karimi","year":"2023","journal-title":"Med Oncol"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100847","article-title":"Liquid biopsy with droplet digital PCR targeted to specific mutations in plasma cell-free tumor DNA can detect ovarian cancer recurrence earlier than CA125","volume":"38","author":"Minato","year":"2021","journal-title":"Gynecol Oncol Rep"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202402658","article-title":"Sensitive circulating tumor DNA-based residual disease detection in epithelial ovarian cancer","volume":"7","author":"Kallio","year":"2024","journal-title":"Life Sci Alliance"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-1429","article-title":"Serial circulating tumor DNA analysis with a tumor-na\u00efve next-generation sequencing panel detects minimal residual disease and predicts outcome in ovarian cancer","volume":"84","author":"Heo","year":"2024","journal-title":"Cancer Res"},{"key":"B264","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091438","article-title":"Advancing leukemia management through liquid biopsy: insights into biomarkers and clinical utility","volume":"17","author":"Hollanda","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100935","article-title":"Rapid screening for individualized chemotherapy optimization of colorectal cancer: a novel conditional reprogramming technology-based functional diagnostic assay","volume":"14","author":"Li","year":"2021","journal-title":"Transl Oncol"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.06.016","article-title":"Personalized drug sensitivity screening for bladder cancer using conditionally reprogrammed patient-derived cells","volume":"76","author":"Kettunen","year":"2019","journal-title":"Eur Urol"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15080394","article-title":"Patient-derived organoid biobanks for translational research and precision medicine: challenges and future perspectives","volume":"15","author":"Di Paola","year":"2025","journal-title":"J Pers Med"},{"key":"B269","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s13046-023-02853-4","article-title":"Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer","volume":"42","author":"Cartry","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2019.09.008","article-title":"Microfluidics for personalized drug screening of cancer","volume":"48","author":"Venugopal Menon","year":"2019","journal-title":"Curr Opin Pharmacol"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1612906114","article-title":"Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.104463","article-title":"Gynecologic cancers in 2025: a year in review","volume":"36","author":"Arenhardt","year":"2026","journal-title":"Int J Gynecol Cancer"},{"key":"B273","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13048-024-01520-2","article-title":"In vitro drug testing using patient-derived ovarian cancer organoids","volume":"17","author":"Chen","year":"2024","journal-title":"J Ovarian Res"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.5009\/gnl250108","article-title":"Patient-derived organoids from multiple sites of a single tumor recapitulates intratumoral heterogeneity in patients with gastric cancer","volume":"20","author":"Yoon","year":"","journal-title":"Gut Liver"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1002\/cai2.70028","article-title":"Re-innovation in clinical trial designs based on precision therapy","volume":"4","author":"Li","year":"2025","journal-title":"Cancer Innov"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2021.1918236","article-title":"Planning for the next pandemic: ethics and innovation today for improved clinical trials tomorrow","volume":"14","author":"McMillan","year":"2022","journal-title":"Stat Biopharm Res"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1007\/s12609-019-00334-2","article-title":"I-SPY 2: a neoadjuvant adaptive clinical trial designed to improve outcomes in high-risk breast cancer","volume":"11","author":"Wang","year":"2019","journal-title":"Curr Breast Cancer Rep"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2017.09.002","article-title":"Re-inventing drug development: a case study of the I-SPY 2 breast cancer clinical trials program","volume":"62","author":"Das","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-004039","article-title":"Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program","volume":"33","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0000000000000855","article-title":"Treatment options for molecular subtypes of endometrial cancer in 2023","volume":"35","author":"Karpel","year":"2023","journal-title":"Curr Opin Obstet Gynecol"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13629","article-title":"Pexidartinib long-term hepatic safety profile in patients with tenosynovial giant cell tumors","volume":"26","author":"Lewis","year":"2021","journal-title":"Oncologist"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2025.110178","article-title":"Advancing the frontier of artificial intelligence on emerging technologies to redefine cancer diagnosis and care","volume":"191","author":"Vyas","year":"2025","journal-title":"Comput Biol Med"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-019-0078-1","article-title":"Artificial intelligence for precision oncology: beyond patient stratification","volume":"3","author":"Azuaje","year":"2019","journal-title":"NPJ Precis Oncol"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(22)00210-2","article-title":"Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts","volume":"5","author":"Fremond","year":"2023","journal-title":"Lancet Digit Health"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16101810","article-title":"Prediction of mismatch repair status in endometrial cancer from histological slide images using various deep learning-based algorithms","volume":"16","author":"Umemoto","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105126","article-title":"Artificial intelligence applications in ovarian cancer detection: a systematic literature review of deep learning approaches and clinical translation challenges","volume":"219","author":"G\u00fclmez","year":"2026","journal-title":"Crit Rev Oncol Hematol"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2024.05.003","article-title":"Deep learning for grading endometrial cancer","volume":"194","author":"Goyal","year":"2024","journal-title":"Am J Pathol"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.28544","article-title":"An integrated clinical-MR radiomics model to estimate survival time in patients with endometrial cancer","volume":"57","author":"Li","year":"2023","journal-title":"J Magn Reson Imaging"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.1001791","article-title":"Analysis of prognostic factors of metastatic endometrial cancer based on surveillance, epidemiology, and end results database","volume":"9","author":"Zhang","year":"2023","journal-title":"Front Surg"},{"key":"B290","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14010005","article-title":"Automated prediction of neoadjuvant chemoradiotherapy response in locally advanced cervical cancer using hybrid model-based MRI radiomics","volume":"14","author":"Yang","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S314289","article-title":"The role of dynamic contrast-enhanced magnetic resonance imaging in predicting treatment response for cervical cancer treated with concurrent chemoradiotherapy","volume":"13","author":"Lu","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B292","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1055\/a-2157-6867","article-title":"Radiomics analysis of multiparametric PET\/MRI for N- and M-staging in patients with primary cervical cancer. Radiomics-Analyse anhand der multiparametrischen PET\/MRT f\u00fcr das N- und M-Staging von Patientinnen mit prim\u00e4rem Zervixkarzinom","volume":"63","author":"Umutlu","year":"2024","journal-title":"Nuklearmedizin"},{"key":"B293","doi-asserted-by":"publisher","DOI":"10.1016\/j.mri.2025.110507","article-title":"The value of multi-parameters MRI based on amide proton transfer imaging in evaluating the efficacy of concurrent radiochemotherapy for locally advanced cervical cancer","volume":"123","author":"Yang","year":"2025","journal-title":"Magn Reson Imaging"},{"key":"B294","doi-asserted-by":"publisher","DOI":"10.1200\/CCI-25-00133","article-title":"Development and assessment of a pipeline for extracting structured data from free-text medical reports using a large language model","volume":"10","author":"Joseph","year":"2026","journal-title":"JCO Clin Cancer Inform"},{"key":"B295","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.21.00017","article-title":"Customizable natural language processing biomarker extraction tool","volume":"5","author":"Holmes","year":"2021","journal-title":"JCO Clin Cancer Inform"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-022-09303-3","article-title":"Is the generalizability of a developed artificial intelligence algorithm for COVID-19 on chest CT sufficient for clinical use? Results from the International Consortium for COVID-19 Imaging AI (ICOVAI)","volume":"33","author":"Topff","year":"2023","journal-title":"Eur Radiol"},{"key":"B297","doi-asserted-by":"publisher","DOI":"10.22037\/aaem.v13i1.2720","article-title":"The role of artificial intelligence in diagnosing pulmonary embolism: a systematic review and meta-analysis","volume":"13","author":"Farzaei","year":"2025","journal-title":"Arch Acad Emerg Med"},{"key":"B298","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2022-000992","article-title":"Diagnostic accuracy of code-free deep learning for detection and evaluation of posterior capsule opacification","volume":"7","author":"Huemer","year":"2022","journal-title":"BMJ Open Ophthalmol"},{"key":"B299","doi-asserted-by":"publisher","first-page":"17051","DOI":"10.1038\/s41598-021-95533-2","article-title":"A real-world demonstration of machine learning generalizability in the detection of intracranial hemorrhage on head computerized tomography","volume":"11","author":"Salehinejad","year":"2021","journal-title":"Sci Rep"},{"key":"B300","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacr.2024.04.027","article-title":"Establishing a validation infrastructure for imaging-based artificial intelligence algorithms before clinical implementation","volume":"21","author":"Ramwala","year":"2024","journal-title":"J Am Coll Radiol"},{"key":"B301","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0307-0","article-title":"The practical implementation of artificial intelligence technologies in medicine","volume":"25","author":"He","year":"2019","journal-title":"Nat Med"},{"key":"B302","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/GRF.0000000000000985","article-title":"Transforming gynecologic cancer care through artificial intelligence: A clinician's guide to the evolving landscape","volume":"69","author":"Polio","year":"2026","journal-title":"Clin Obstet Gynecol"},{"key":"B303","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ijgo.70094","article-title":"Artificial intelligence in the diagnosis and management of gynecologic cancer","volume":"171","author":"Paiboonborirak","year":"2025","journal-title":"Int J Gynaecol Obstet"},{"key":"B304","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13091619","article-title":"Comprehensive genomic profiling and therapeutic implications for patients with advanced cancers: The experience of an academic hospital","volume":"13","author":"Teuwen","year":"2023","journal-title":"Diagnostics (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1785469\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:32:13Z","timestamp":1775539933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1785469\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":304,"alternative-id":["10.3389\/fonc.2026.1785469"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1785469","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"article-number":"1785469"}}